524606 — Beryl Drugs Cashflow Statement
0.000.00%
- IN₹101.33m
- IN₹132.64m
- IN₹211.46m
Annual cashflow statement for Beryl Drugs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 3.48 | -9.5 | 9.84 | 10.1 | 8.66 |
Depreciation | |||||
Non-Cash Items | -1.3 | 2.92 | 2.88 | 3.25 | 3.96 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -11.1 | -7.15 | 3.94 | -17.2 | 1.29 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 3.78 | -2.87 | 24.8 | 8.2 | 26.4 |
Capital Expenditures | -10.5 | -4.16 | -15.6 | -13.5 | -21.9 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 13.1 | 9.53 | 2.62 | 2.7 | 17.9 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 2.55 | 5.38 | -13 | -10.8 | -3.97 |
Financing Cash Flow Items | -4.66 | -4.34 | -4.16 | -4.49 | -5.3 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -5.77 | -4.32 | -11.7 | 1.03 | -15.5 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.558 | -1.81 | 0.117 | -1.58 | 6.89 |